Plant Name: Heliotropium hirsutum
Taxonomic Information:
Plant ID: NPO10915
Plant Latin Name: Heliotropium hirsutum
Taxonomy Genus: Heliotropium
Taxonomy Family: Heliotropiaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCMGeographical Distribution:
China
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| PIK3CA; PIK3CB; GFER; NQO2; | |
| CA2; CA1; CA12; CA9; CA13; CA5B; CA3; CA14; CA5A; CA4; CA6; CA7; | |
| ESR1; | |
| PTGS1; MAOA; PTGS2; | |
| HIF1A; TP53; | |
| SLC6A2; | |
| HTT; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.112E-12 | 4.600E-09 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, NQO2, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.131E-11 | 1.027E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.011E-09 | 2.737E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.216E-08 | 1.471E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.574E-08 | 1.653E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NQO2, PTGS1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.155E-08 | 3.123E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 2.442E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.849E-07 | 3.538E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 6.633E-07 | 3.801E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.306E-06 | 6.772E-04 | APP, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, TP53 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.527E-06 | 7.559E-04 | APP, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.197E-33 | 9.138E-29 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.900E-25 | 2.069E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.176E-06 | 1.030E-03 | PTGS1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.974E-06 | 1.766E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 6.523E-06 | 2.732E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0010038; response to metal ion | 6.674E-06 | 2.742E-03 | APP, CA2, CYP1A2, HIF1A, PTGS2, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.765E-05 | 6.404E-03 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.832E-24 | 3.175E-20 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.753E-32 | 4.541E-30 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA4, CA7, CA6, CA9, CA14, CA13 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.152E-08 | 6.971E-07 | CYP2C9, APP, MAOA, CYP2C19, PTGS2, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.697E-08 | 1.894E-06 | CYP2C9, MAOA, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 8.255E-08 | 2.497E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.126E-07 | 2.724E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19, PTGS2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 6.961E-07 | 1.404E-05 | PIK3CA, PIK3CB, TP53, ESR1, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.243E-06 | 2.148E-05 | PIK3CA, PIK3CB, PTGS2, PTGS1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.876E-06 | 2.837E-05 | CYP2C9, CYP2C19, PTGS2, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.565E-06 | 3.448E-05 | PIK3CA, PIK3CB, TP53, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.988E-06 | 1.099E-04 | PIK3CA, PIK3CB, TP53, HIF1A, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 6.972E-06 | 8.436E-05 | PIK3CA, PIK3CB, PTGS2, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 7.215E-05 | 6.716E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 5.775E-05 | 5.823E-04 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 8.872E-05 | 7.136E-04 | PIK3CA, PIK3CB, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 9.322E-05 | 7.136E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.127E-04 | 7.136E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 9.787E-05 | 7.136E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 2.409E-04 | 1.166E-03 | PIK3CA, PIK3CB, PTGS2, HIF1A, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.180E-04 | 7.136E-04 | PIK3CA, PIK3CB, TP53 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.127E-04 | 7.136E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.466E-04 | 8.028E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 1.180E-04 | 7.136E-04 | PIK3CA, PIK3CB, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.528E-04 | 8.028E-04 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.592E-04 | 8.028E-04 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 2.862E-04 | 1.332E-03 | PIK3CA, PIK3CB, TP53 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 3.362E-04 | 1.507E-03 | PIK3CA, PIK3CB, TP53 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.592E-04 | 8.028E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.915E-04 | 1.692E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 4.152E-04 | 1.732E-03 | PIK3CA, PIK3CB, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.397E-04 | 1.774E-03 | PIK3CA, PIK3CB, HIF1A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 5.330E-04 | 2.015E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 7.207E-04 | 2.491E-03 | PIK3CA, PIK3CB, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 6.868E-04 | 2.444E-03 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 6.868E-04 | 2.444E-03 | PIK3CA, PIK3CB, TP53 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.074E-03 | 3.418E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 9.873E-04 | 3.229E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 9.257E-04 | 3.111E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.212E-03 | 3.759E-03 | PIK3CA, PIK3CB, TP53 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.608E-03 | 4.526E-03 | CYP2C9, MAOA, CYP1A2, PTGS2, CYP2C19, CYP3A4, PTGS1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.520E-03 | 4.409E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 3.057E-03 | 7.880E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 3.186E-03 | 7.880E-03 | PIK3CA, PIK3CB, TP53 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 3.871E-03 | 9.368E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.084E-03 | 7.880E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 2.197E-03 | 5.908E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 3.191E-03 | 7.880E-03 | CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 1.455E-03 | 4.402E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 1.934E-03 | 5.317E-03 | PIK3CA, PIK3CB |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.530E-03 | 4.409E-03 | MAOA, CYP1A2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 5.040E-04 | 1.967E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; PTGS2; PIK3CB; NQO2; CA9; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
